Rajeshwary Ghosh1, Sumanta K Goswami2, Luis Felipe B B Feitoza1, Bruce Hammock2, Aldrin V Gomes3. 1. Department of Neurobiology, Physiology and Behavior, University of California, Davis, CA 95616, United States. 2. Department of Entomology and Nematology and Comprehensive Cancer Center, University of California, Davis, CA 95616, United States. 3. Department of Neurobiology, Physiology and Behavior, Department of Physiology and Membrane Biology, University of California, Davis, CA 95616, United States. Electronic address: avgomes@ucdavis.edu.
Abstract
BACKGROUND: One of the most common nonsteroidal anti-inflammatory drugs (NSAIDs) used worldwide, diclofenac (DIC), has been linked to increased risk of cardiovascular disease (CVD). The molecular mechanism(s) by which DIC causes CVD is unknown. METHODS: Proteasome activities were studied in hearts, livers, and kidneys from male Swiss Webster mice treated with either 100mg/kg DIC for 18h (acute treatment) or 10mg/kg DIC for 28days (chronic treatment). Cultured H9c2 cells and neonatal cardiomyocytes were also treated with different concentrations of DIC and proteasome function, cell death and ROS generation studied. Isolated mouse heart mitochondria were utilized to determine the effect of DIC on various electron transport chain complex activities. RESULTS: DIC significantly inhibited the chymotrypsin-like proteasome activity in rat cardiac H9c2 cells, murine neonatal cardiomyocytes, and mouse hearts, but did not affect proteasome subunit expression levels. Proteasome activity was also affected in liver and kidney tissues from DIC treated animals. The levels of polyubiquitinated proteins increased in hearts from DIC treated mice. Importantly, the levels of oxidized proteins increased while the β5i immunoproteasome activity decreased in hearts from DIC treated mice. DIC increased ROS production and cell death in H9c2 cells and neonatal cardiomyocytes while the cardioprotective NSAID, aspirin, had no effect on ROS levels or cell viability. DIC inhibited mitochondrial Complex III, a major source of ROS, and impaired mitochondrial membrane potential suggesting that mitochondria are the major sites of ROS generation. CONCLUSION: These results suggest that DIC induces cardiotoxicity by a ROS dependent mechanism involving mitochondrial and proteasome dysfunction.
BACKGROUND: One of the most common nonsteroidal anti-inflammatory drugs (NSAIDs) used worldwide, diclofenac (DIC), has been linked to increased risk of cardiovascular disease (CVD). The molecular mechanism(s) by which DIC causes CVD is unknown. METHODS: Proteasome activities were studied in hearts, livers, and kidneys from male Swiss Webster mice treated with either 100mg/kg DIC for 18h (acute treatment) or 10mg/kg DIC for 28days (chronic treatment). Cultured H9c2 cells and neonatal cardiomyocytes were also treated with different concentrations of DIC and proteasome function, cell death and ROS generation studied. Isolated mouse heart mitochondria were utilized to determine the effect of DIC on various electron transport chain complex activities. RESULTS:DIC significantly inhibited the chymotrypsin-like proteasome activity in rat cardiac H9c2 cells, murine neonatal cardiomyocytes, and mouse hearts, but did not affect proteasome subunit expression levels. Proteasome activity was also affected in liver and kidney tissues from DIC treated animals. The levels of polyubiquitinated proteins increased in hearts from DIC treated mice. Importantly, the levels of oxidized proteins increased while the β5i immunoproteasome activity decreased in hearts from DIC treated mice. DIC increased ROS production and cell death in H9c2 cells and neonatal cardiomyocytes while the cardioprotective NSAID, aspirin, had no effect on ROS levels or cell viability. DIC inhibited mitochondrial Complex III, a major source of ROS, and impaired mitochondrial membrane potential suggesting that mitochondria are the major sites of ROS generation. CONCLUSION: These results suggest that DIC induces cardiotoxicity by a ROS dependent mechanism involving mitochondrial and proteasome dysfunction.
Authors: Casey L Quinlan; Adam L Orr; Irina V Perevoshchikova; Jason R Treberg; Brian A Ackrell; Martin D Brand Journal: J Biol Chem Date: 2012-06-11 Impact factor: 5.157
Authors: Dairong Wang; Vickas V Patel; Emanuela Ricciotti; Rong Zhou; Mark D Levin; Ehre Gao; Zhou Yu; Victor A Ferrari; Min Min Lu; Junwang Xu; Hualei Zhang; Yiqun Hui; Yan Cheng; Nataliya Petrenko; Ying Yu; Garret A FitzGerald Journal: Proc Natl Acad Sci U S A Date: 2009-04-17 Impact factor: 11.205
Authors: Phung N Thai; Lu Ren; Wilson Xu; James Overton; Valeriy Timofeyev; Carol E Nader; Michael Haddad; Jun Yang; Aldrin V Gomes; Bruce D Hammock; Nipavan Chiamvimonvat; Padmini Sirish Journal: Cardiovasc Drugs Ther Date: 2021-09-09 Impact factor: 3.727
Authors: Amrita Ahluwalia; Neil Hoa; Michael K Jones; Andrzej S Tarnawski Journal: Am J Physiol Gastrointest Liver Physiol Date: 2019-09-23 Impact factor: 4.052
Authors: Péter Ferdinandy; István Baczkó; Péter Bencsik; Zoltán Giricz; Anikó Görbe; Pál Pacher; Zoltán V Varga; András Varró; Rainer Schulz Journal: Eur Heart J Date: 2019-06-07 Impact factor: 29.983
Authors: G Piccirillo; D A Carvajal Berrio; A Laurita; A Pepe; B Bochicchio; K Schenke-Layland; S Hinderer Journal: Sci Rep Date: 2019-03-05 Impact factor: 4.379
Authors: Adrian Paul Duval; Laetitia Troquier; Olga de Souza Silva; Nicolas Demartines; Olivier Dormond Journal: Cancers (Basel) Date: 2019-09-27 Impact factor: 6.639